FTY720 and lung tumor development

International Immunopharmacology

Volumn 9, Issue 6, 2009, Pages 689-693

  Salinas, Natália Regina Antunes ^a   Oshima, Celina Tizuko Fujiyama ^a   Cury, Patrícia Maluf ^b   Cordeiro, José Antonio ^c   Bueno, Valquiria ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^c FAMERP Sao Jose do Rio Preto Medical School   (Brazil)

Author keywords

FTY720; Lung tumor; Lymphocytes; PCNA; Urethane; VEGF

Indexed keywords

CYCLINE; FINGOLIMOD; URETHAN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG ADENOMA; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMA; ANIMALS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPYLENE GLYCOLS; SPHINGOSINE; URETHANE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349153065     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.12.007     Document Type: Article

References (35)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., and Ghafoor A. Cancer statistics 2005. CA Cancer J Clin 55 (2005) 10-30
2. Gazdar A.F., and Linnoila R.I. The pathology of lung cancer - changing concepts and newer diagnostic techniques. Semin Oncol 15 (1998) 215-225
3. Malkinson A.M. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 24 (1998) 541-555
4. Manson R.J., Kalina M., Nielsen L.D., Malkinson A.M., and Shannon J.M. Surfactant protein C expression in urethane-induced murine pulmonary tumors. Am J Pathol 156 (2000) 175-182
5. Malkinson A.M., and Beer D.S. Major effect on susceptibility to urethane-induced pulmonary adenoma by a single gene in BALB/cBy mice. J Natl Cancer Inst 70 (1983) 931-936
6. Wang M., Devereux T.R., Vikis H.G., NcCulloch S.D., Holliday W., and Anna C. Pol iota is a candidate for the mouse pulmonary adenoma resistance 2 locus, a major modifier of chemically induced lung neoplasia. Cancer Res 64 (2004) 1924-1931
7. O'Donnell E.P., Zerbe L.K., Dwyer-Nield L.D., Kisley L.R., and Malkinson A.M. Quantitative analysis of early chemically-induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis. Cancer Lett 241 (2006) 197-202
8. + T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med 191 (2000) 113-118
9. + T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94 (2003) 1003-1009
10. + T cells is a favorable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94 (2006) 275-280
11. + T cells in antitumor immunity. Trends Immunol 22 (2001) 269-276
12. + T cells: new strategies for cancer vaccine design. J Immunother 24 (2001) 195-204
13. Adachi K., Kohara T., Nakao N., Arita M., Chiba K., Mishina T., et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propnediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 5 (1995) 853-856
14. Nagahara Y., Enosawa S., Ikekita M., Suzuki S., and Shinomiya T. Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology 48 (2000) 75-85
15. Wang J.D., Takahara S., Nonomura N., Ichimaru N., Toki K., Azuma H., et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 40 (1999) 50-55
16. Tanaka T., Takahara S., Hatori M., Suzuki K., Wang J.D., Ichimaru N., et al. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett 181 (2002) 165-171
17. Azuma H., Takahara S., Ichimaru N., Wang J.D., Itoh Y., Otsuki Y., et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 62 (2002) 1410-1419
18. Matsumoto M.A., Filho H.N., Jorge F.M., Salvadori D.M., Marques M.E., and Ribeiro D.A. Expression of cell cycle regulatory proteins in epithelial components of dental follicles. J Mol Histol 37 (2006) 127-131
19. Avanzo J.L., Mesnil M., Hernandez-Blazquez F.J., da Silva T.C., Fukumasu H., Mori C.M., et al. Altered expression of connexins in urethane-induced mouse lung adenomas. Life Sci 79 (2006) 2202-2208
20. Luau C.L., D'Amico Jr. T.A., and Harpoler D.H. Clinical an molecular prognostic factors and models for non-small cell lung cancer. In: Pass H.I., Mitchell J.B., Johnson D.H., Turisi A.T., and Minna J.D. (Eds). Lung cancer: principles and practice (1998), Lippincott, Williams & Wilkins, Philadelphia 602-611
21. Sarasin A. An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat Res 544 (2003) 99-106
22. Herzig M., and Christofori G. Recent advances in cancer research: mouse models of tumorigenesis. Biochim Biophys Acta 1602 (2002) 97-113
23. Benfield J.R., Malkinson A.M., Schuller H.M., and Sunday M.E. Preclinical models of lung cancer. In: Kane M.A., and Bunn P.A. (Eds). Biology of lung cancer (1998), Marcel Dekker, Inc, New York 247-293
24. + T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant 19 (2004) 702-713
25. Chiba K., Yanagawa Y., Nasubuchi Y., Kataoka H., Kawaguchi T., and Ohtsuki M. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. 1. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160 (1998) 5037-5044
26. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., and Xie J. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
27. Galvão V.R., Ginoza M., Franco M., Burdmann E.A., and Bueno V. Prolonged administration of FTY720 does not cause renal toxicity in mice. Transplant Proc 37 (2005) 112-113
28. Tumuluri V., Thomas G.A., and Fraser I.S. The relationship of proliferating cell density at the invasive tumour front with prognostic and risk factors in human oral squamous cell carcinoma. J Oral Pathol Med 33 (2004) 204-208
29. Linden M.D., Torres F.X., Kubus J., and Zarbo R.J. Clinical application of morphologic and immunocytochemical assessments of cell proliferation [editorial]. Am J Clin Pathol 97 (1992) S4-S13
30. Monobe Y., and Manabe T. Morphological changes and proliferative activity of alveolar epithelium in mouse lungs treated with urethane. Virchows Arch 425 (1995) 583-588
31. Bremnes R.M., Camps C., and Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and vFGF in tumours and blood. Lung Cancer 51 (2006) 143-158
32. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 32 (1996) 2413-2422
33. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., and Luh K.T. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small cell lung cancer. J Clin Oncol 19 (2001) 432-441
34. Yilmaz A., Ernam D., Unsal E., Demirag F., Atikcan S., and Tastepe I. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res 38 (2007) 764-768
35. LaMontagne K., Littlewood-Evans A., Schnell C., O'Reilly T., Wyder L., Sanchez T., et al. Antagonism of sphigosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66 (2006) 221-231